All data necessary to replicate our study's findings is available in the paper and its supporting files.

Introduction {#sec001}
============

Mammary gland cancer is among the most prevalent forms of cancer in women \[[@pone.0233232.ref001]\]. In Japan, more than 70,000 women are diagnosed of mammary gland cancer every year \[[@pone.0233232.ref002]\].

However, not all the patients can be cured at present. The development of suitable animal models for understanding the underlying mechanism as well as for identifying novel preventive and therapeutic approaches are required.

At present, rodents are used in most of the studies associated with breast cancers \[[@pone.0233232.ref003]\], although they are different from human beings in terms of both the biological characteristics and molecular mechanisms underlying development and progression of breast cancers, which limit their application in breast cancer research.

*Tupaia belangeri* is a small non-primate mammal belonging to the family Tupaiidae, which has a body weight of approximately 150 g \[[@pone.0233232.ref004]\]. In comparison with rodents, the genome sequence of tree shrew shows a higher homology with that of primates \[[@pone.0233232.ref004]--[@pone.0233232.ref006]\]. The tree shrew shows susceptibility to hepatitis viruses infections (hepatitis C virus \[[@pone.0233232.ref007], [@pone.0233232.ref008]\], hepatitis B virus \[[@pone.0233232.ref009], [@pone.0233232.ref010]\]) and can be used for the evaluation of anti-depressant drugs \[[@pone.0233232.ref011]\]. In addition, the development and physiological characters of the tree shrew's mammary gland are similar to those of human beings \[[@pone.0233232.ref012], [@pone.0233232.ref013]\].

A previous study observed incidences of tumors (intraductal mammary adenocarcinoma) in the tree shrew's mammary glands (5/1,132, 0.44%) \[[@pone.0233232.ref014]\]. To characterize spontaneous mammary tumor in a tree shrew model, we investigated the morphogenesis of spontaneous mammary tumor in the tree shrew by pathologic analysis, and characterized its lineage.

Materials and methods {#sec002}
=====================

Animals {#sec003}
-------

The tree shrews used in this study were originally obtained from the Laboratory Animal Center at the Kunming Institute of Zoology and Chinese Academy of Sciences, Kunming, China (10 male and 20 female) and breed in our animal facility. A total of 61 female tree shrews were used in this study. This study was carried out following the Guidelines of Animal Experimentation of the Japanese Association for Laboratory Animal Science and Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All experimental protocols were approved by the institutional review boards of the regional ethics committees of Kagoshima University (VM15051 and VM13044).

The animals were individually housed in cages and fed a daily regimen of eggs, fruit, water, and dry marmoset food (CMS1M, Crea). The animals were humanely handled in accordance with the Institutional Animal Care and Use Committee for Laboratory Animals. During surgery, animals were anesthesized by intramuscular injection of ketamine (50 mg/kg) and atropine (0.33 mg/kg) and anesthesia was maintained with 2% isoflurane (Fujifilm-Wako Co.). Mammary tumors were detected by eye observation every day, and mammary tumors with more than 1 cm in diameter were subjected to surgical excision. After surgery, animals were returned to Laboratory Animal Center.

Cytodiagnosis, histochemical analysis, and immunohistochemistry staining {#sec004}
------------------------------------------------------------------------

Mammary tumor in tree shrews was diagnosed by cytodiagnosis and histology after surgery. Excised tissues were stained with May-Giemsa (Sigma-Aldrich Co.) for cytodiagnosis. Also, the tissues were fixed with 10% neutral buffered formalin solution (Wako), and stained with hematoxylin and eosin (H&E) for tissue histology. The Histofine Simple Stain MAX-PO Multi system (Nichirei) was used for immunohistochemical staining. The following primary antibodies were used for immunohistochemistry staining: anti-estrogen receptor (ER)-α (1:50 dilution, mouse monoclonal antibody (MoAb) clone 1D5, DAKO), progesterone receptor (PR) (1:1,000, rabbit polyclonal, clone C-19, Santa Cruz), human epidermal growth factor receptor (HER)2 (1:250, rabbit MoAb clone A0485, DAKO), and Ki67 (1:50, mouse MoAb, clone MIB-1, DAKO) antibodies. Detected antigens were visualized with 3, 3ʹ-diaminobenzine tetrahydrochloride reagent. Sections were counter stained with Mayer's hematoxylin. Histopathological diagnosis was made based on classification of mammary tumors in domestic animals \[[@pone.0233232.ref015]\]. Evaluation of ER, PR, HER-2, and Ki-67 positive ratio was performed as described in [S1 File](#pone.0233232.s007){ref-type="supplementary-material"} and [S1 Table](#pone.0233232.s005){ref-type="supplementary-material"}.

Gene mutation analysis {#sec005}
----------------------

Gene mutations in tumor tissues were analyzed as described previously \[[@pone.0233232.ref012]\]. Briefly, total RNA from tumor tissues was extracted using an ISOGEN Kit (Nippon Gene) according to the manufacturer's instructions. cDNA was synthesized using a SuperScript III Reverse Transcriptase kit (Invitrogen) following the manufacturer's instructions. Gene-specific PCR targeting of PTEN and PIK3CA genes was performed, and the amplified product was subcloned and sequenced. The primers used to amplify the candidate genes PTEN and PIK3CA were as follows: PTEN forward `5′-ATGACAGCCATCATCAAAGAG-3′` and reverse `5′-TCAGACTTTTGTAATTTGTG-3′`; PIK3CA forward `5′-ATGCCTCCACGACCAT CA-3′` and reverse `5′-TCAGTTCAATGCATGCTG-3′`.

Flow cytometric analysis {#sec006}
------------------------

Tumor tissues were digested with Hank's balanced salt solution (HBSS; Life Technologies) containing 5 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES), 2% fetal bovine serum (FBS), 1 mg/mL collagenase (Wako Pure Chemical Industries), and 0.1% DNase I (Life Technologies), as described \[[@pone.0233232.ref016]\]. A total number of 10^6^ cells were labeled with 0.5 μg of primary Ab (anti-nectin-4 goat polyclonal Antibody (R&D systems)) or isotype control in 100 μL of HBSS (Life Technologies) containing 2% FBS and HEPES, and then with an Alexa-Fluor-488-conjugated anti-goat IgG Ab (Life Technologies) diluted 1:500. To exclude dead cells, 7-AAD (Beckman Coulter) was used in the analysis. The cells were analyzed with a BD FACS Verse flow cytometer (BD Co.), and the data were processed using the Flow Jo FACS analysis software ver. 9.5.3.

X-ray CT analysis {#sec007}
-----------------

X-ray CT analysis of tree shrews was performed using Latheta LCT-200 (Hitachi Co. Ltd.) under anesthesia.

Results {#sec008}
=======

Onset of mammary gland tumors {#sec009}
-----------------------------

We characterized 61 female tree shrews, out of which 15 were found to have mammary tumors ([Fig 1](#pone.0233232.g001){ref-type="fig"}). The surgical excision history of mammary gland tumors is summarized in [Table 1](#pone.0233232.t001){ref-type="table"}. The incidence rate of mammary tumors was 24.6% (15/61) and the average age of tumor incidence was 2 years 3 months. The simultaneous or metachronous case of mammary tumors was observed in 9 tree shrews (No.121, 75, 97, 130, 131, 184, 185, 26, and 27) and the rate was 60.0% (9/15). The mammary tumor usually occurs in two- to three-year old virgin tree shrews. The occurrence of mammary tumor in a 10-month-old tree shrew (No. 211) indicates its existence in juvenile individuals.

![Onset of mammary tumors in female tree shrews was indicated.\
Initial onset age of spontaneous mammary tumors in tupaia is indicated. Each tupaia ID number is indicated on the horizontal line.](pone.0233232.g001){#pone.0233232.g001}

10.1371/journal.pone.0233232.t001

###### Summary of tree shrews with mammary tumors.

![](pone.0233232.t001){#pone.0233232.t001g}

  Tree shrew No.   Date of surgery                                 Date of birth                                Age at surgery                                    Histology                                     Markers[\*^3^](#t001fn003){ref-type="table-fn"}
  ---------------- ----------------------------------------------- -------------------------------------------- ------------------------------------------------- --------------------------------------------- -------------------------------------------------
  No.26            2016/1/19                                       2012/2/26                                    3Y 10 M[\*^4^](#t001fn004){ref-type="table-fn"}   IPA[\*^1^](#t001fn001){ref-type="table-fn"}   ER, PR, Ki67
  2016/2/4         3Y 11 M                                         IPA                                          ER, PR, Ki67, Her2                                                                              
  2016/8/30        4Y 6 M                                          IPA                                          ER, PR, Ki67                                                                                    
  2017/1/26        4Y 11M                                          IPA                                          ER, PR, Ki67, Her2                                                                              
  No.27            2017/1/6                                        2012/4/11                                    4Y7 M                                             NT[\*](#t001fn006){ref-type="table-fn"}       NT
  2017/2/9         4Y 8 M                                                                                                                                                                                       
  2017/9/12        5Y 5 M                                                                                                                                                                                       
  No.48            2016/1/19                                       2013/8/5                                     2Y 5M                                             IPA                                           ER, PR, Ki67
  No.75            2015/6/16                                       2013/9/20                                    1 Y 8 M                                           NT                                            NT
  2016/6/19        4Y 3M                                           IPA                                          ER, PR, Ki67                                                                                    
  2018/2/20        6Y 1M[\*^5^](#t001fn005){ref-type="table-fn"}   TC[\*^2^](#t001fn002){ref-type="table-fn"}   ER, PR, Ki67, Her2                                                                              
  No.97            2017/10/26                                      2013/11/9                                    3Y 11M                                            IPA                                           ER, PR, Ki67
  2017/10/31       3Y 11 M                                         IPA                                          PR, Ki67                                                                                        
  2018/01/15       4Y 2 M                                          IPA                                          ER, PR, Ki67                                                                                    
  2018/01/30       4Y 2 M                                          IPA                                          PR, Ki67                                                                                        
  No.107           2017/1/10                                       2014/2/27                                    2 Y 11 M                                          NT                                            NT
  No.121           2015/10/14                                      2014/5/30                                    1Y4 M                                             IPA                                           ER, PR, Ki67
  2017/8/1         3Y 2 M                                          IPA                                          PR, Ki67                                                                                        
  2017/12/15       3Y 9M                                           IPA                                          ER, PR, Ki67                                                                                    
  No.128           2018/01/15                                      2014/06/20                                   3Y 9 M                                            IPA                                           ER, PR, Ki67
  No.130           2016/8/30                                       2014/6/23                                    2Y 2 M                                            IPA                                           ER, PR, Ki67
  2016/9/21        2 Y 3 M                                         NT                                           NT                                                                                              
  No.131           2016/4/13                                       2014/6/23                                    1Y 10 M                                           NT                                            NT
  2017/6/2         3 Y                                             IPA                                          PR, Ki67                                                                                        
  2018/2/14        3Y 7M                                           IPA                                          ER, PR, Ki67, Her2                                                                              
  2019/12/13       5Y 6M                                           TC                                           NT                                                                                              
  No.146           2017/1/6                                        2014/10/24                                   2 Y 3 M                                           NT                                            NT
  No.155           2017/12/15                                      2014/10/30                                   3Y 1 M                                            IPA                                           ER, PR, Ki67
  No.184           2017/6/14                                       2015/2/17                                    2Y 4M                                             IPA                                           ER, PR, Ki67
  2018/2/20        3Y                                              IPA                                          ER, PR, Ki67                                                                                    
  No.185           2017/4/19                                       2015/2/17                                    2 Y 2M                                            NT                                            NT
  2017/10/19       2 Y 8M                                          IPA                                          PR, Ki67                                                                                        
  No.211           2016/4/27                                       2015/6/25                                    10 M                                              IPA                                           ER, PR, Ki67

\*^1^ Intraductal papillary adenoma

\*^2^ Tubulopapillary carcinomas

\*^3^ Markers with positive reaction

\*^4^ Year; Y, Months; M

\*^5^found dead and indicated with red colored text

\*NT: not tested

Influence of inheritance on mammary gland tumors in tree shrews {#sec010}
---------------------------------------------------------------

The parent-child relationship in the tree shrew was summarized in [Fig 2](#pone.0233232.g002){ref-type="fig"}. Mammary tumor was detected in 66.7% (4/6) of the offspring of No. 3. However, all (100%) of the offspring of No. 9 (5/5, No. 48, 128, 130,131, 155) and 11 (5/5, No. 75, 146, 184, 185, 211) developed mammary tumors. These high incidence rate of mammary gland tumors is indicative of the character of familial cancers \[[@pone.0233232.ref017]\] and possible influence of inheritance factors. Tree shrews No. 3 and 9 did not develop mammary tumors; therefore, unknown factor(s) inherited from the male may have influenced the incidences in the offspring.

![Lineage of tree shrew parents and offsprings.\
Brown color indicates female and black color indicates male tree shrew. Tree shrew numbers with red color indicate the possible familial mammary tumor and blue circle indicates the simultaneous or metachronous multiple tumors. Red circle indicates the incidence of malignant carcinoma.](pone.0233232.g002){#pone.0233232.g002}

Characteristics of spontaneous mammary gland tumors in tree shrews {#sec011}
------------------------------------------------------------------

The mammary tumors in tree shrews were oval or irregular, with smooth surface, and were frequently complicated with ulcer (No. 75: 1 year and 8 months, [Fig 3A](#pone.0233232.g003){ref-type="fig"}). A malignant case with large tumors with ulcer was recorded (No. 75: 6 years and 1 month, [Fig 3B](#pone.0233232.g003){ref-type="fig"}). Cytodiagnosis suggested tree shrew mammary tumors to be malignant epithelial tumors (No. 26, [Fig 3C](#pone.0233232.g003){ref-type="fig"}). Mammary tumor with sheet-like clump and strong conjunction of tumor cells suggested the epidermal origin of cell clump. Mammary tumor cells were basophilic and their nucleus showed atypical morphology (in terms of size and nucleolus size).

![(**A**) Outlook of tree shrew spontaneous mammary tumor (No.75 intraductal papillary adenomas, 4 yeas 3 months old), (**B**) tubulopapillary carcinoma (No.75, 6 year 1 month old), and (**C**) cytodiagnosis of tree shrew No.26 mammary gland tumor (3 year 10monts old). Tumor cells are showing features of malignant epithelial tumor.](pone.0233232.g003){#pone.0233232.g003}

Based on histopathological examinations, mammary gland tumors were divided into following 2 types ([Fig 4](#pone.0233232.g004){ref-type="fig"}): intraductal papillary adenomas were observed in 22 cases ([Fig 4A and 4B](#pone.0233232.g004){ref-type="fig"}, [Table 2](#pone.0233232.t002){ref-type="table"}) and tubulopapillary carcinomas were observed in 2 cases (No. 75, 131; [Fig 4C and 4D](#pone.0233232.g004){ref-type="fig"}, [Table 2](#pone.0233232.t002){ref-type="table"}). Intraductal papillary adenomas had an intraductal, papillary, arborescent growth pattern in which the neoplastic epithelial cells were supported by a fibrovascular stalk. The neoplastic epithelial cells of the papillae, which form a single to double layer, have an oval nucleus and a small amount of cytoplasm. A layer of inconspicuous flattened myoepithelial cells was observed below the neoplastic epithelial cells. Anisokaryosis and anisocytosis were minimal, with low mitotic activity. Tubulopapillary carcinomas were composed of neoplastic epithelial cells arranged in a tubular and papillary pattern. Nuclear/cytoplasm ratio of tumor cells was high, and nucleus showed size variation and atypical morphology. The tumor cells had high mitotic activities and invaded the surrounding mammary tissues ([Fig 4C and 4D](#pone.0233232.g004){ref-type="fig"}) \[[@pone.0233232.ref018]\]. Pulmonary metastasis was observed in one case (No. 131, at 5 year 6 months of age).

![HE staining of tree shrew mammary gland tumors (bar = 100μm).\
Intraductal papillary adenomas (tree shrew No.97, 3 years 11 months old, **A, B**) and tubulopapillary carcinoma in tree shrew No.75 (6 years 1 month old, **C, D**).](pone.0233232.g004){#pone.0233232.g004}

10.1371/journal.pone.0233232.t002

###### Characteristics of tree shrew mammary gland tumors.

![](pone.0233232.t002){#pone.0233232.t002g}

  Tree shrew No.   Age at surgery   Histology                                     Position[^\#^](#t002fn003){ref-type="table-fn"}   ER[\*](#t002fn004){ref-type="table-fn"}   PR[\*](#t002fn004){ref-type="table-fn"}   Ki67[\*](#t002fn004){ref-type="table-fn"}   HER-2
  ---------------- ---------------- --------------------------------------------- ------------------------------------------------- ----------------------------------------- ----------------------------------------- ------------------------------------------- -------
  No.26            3Y10 M           IPA[\*^1^](#t002fn001){ref-type="table-fn"}   LR3                                               3a                                        3b                                        11.8                                        0
  3Y 11 M          IPA              R1                                            3a                                                3b                                        9.7                                       1+                                          
  4Y 6 M           IPA              R3                                            3b                                                3b                                        27.2                                      1+                                          
  4Y 11 M          IPA              MG                                            3a                                                3b                                        18                                        0                                           
  No.48            2Y 5 M           IPA                                           L3                                                3b                                        3b                                        33.4                                        0
  No.75            4 Y 3 M          IPA                                           PN                                                3b                                        3b                                        15.3                                        0
  6 Y 1 M          TC               MG                                            1                                                 2                                         68.1                                      2+                                          
  No.97            3 Y 11 M         IPA                                           L3                                                3a                                        3b                                        6.7                                         0
  3 Y 11 M         IPA              L1-2                                          1                                                 3a                                        6.1                                       0                                           
  4 Y 2 M          IPA              L1                                            2                                                 3b                                        25.4                                      0                                           
  4 Y 2 M          IPA              L2                                            1                                                 3a                                        22.6                                      0                                           
  No.121           1 Y 4 M          IPA                                           L1                                                3a                                        3b                                        34.7                                        0
  3 Y 2 M          IPA              L1                                            0                                                 3b                                        7.4                                       0                                           
  3 Y 9 M          IPA              LMG                                           3a                                                3b                                        20.9                                      0                                           
  No.128           3 Y 9 M          IPA                                           PN                                                1                                         2                                         6.9                                         0
  No.130           2 Y 2 M          IPA                                           LR3                                               3b                                        3b                                        30.8                                        0
  No.131           3 Y              IPA                                           MG                                                0                                         3b                                        5.5                                         0
  3 Y 7 M          IPA              MG                                            3b                                                3b                                        16.2                                      1+                                          
  No.155           3 Y 1 M          IPA                                           R3                                                2                                         3b                                        25.3                                        0
  No.184           2 Y 4 M          IPA                                           L2                                                1                                         3b                                        7.9                                         0
  3yr              IPA              MG                                            3b                                                3b                                        57.2                                      0                                           
  No.185           2 Y 8 M          IPA                                           Last MG                                           1                                         3b                                        17.2                                        0
  No.211           10 M             IPA                                           1--2                                              3b                                        3b                                        51.9                                        0

\*^1^ Intraductal papillary adenomas

\*^2^ Tubulopapillary carcinomas

\#LR: left and right, MG: mammary gland, PN: pubic neighborhood, number: position of tumors

\*J-score ([S1 Table](#pone.0233232.s005){ref-type="supplementary-material"})

Mammary gland tumor markers of tree shrews {#sec012}
------------------------------------------

Mammary tumor cells were reported to be stained with estrogen receptor α (ERα), progesterone receptor (PR) and HER-2 in human \[[@pone.0233232.ref019]\] as well as tree shrew \[[@pone.0233232.ref012], [@pone.0233232.ref013]\] ([Table 2](#pone.0233232.t002){ref-type="table"}). Staining was done for these markers in tree shrew mammary tumor tissues ([Fig 5](#pone.0233232.g005){ref-type="fig"}). Out of 23 characterized cases, 21 were ER positive (91.3%) and 100% were positive for PR ([Table 2](#pone.0233232.t002){ref-type="table"}, [Fig 5](#pone.0233232.g005){ref-type="fig"}). All cases were ER or PR positive; therefore, they could be classified as the luminal type \[[@pone.0233232.ref020]\]. Also in the malignant case (tree shrew No. 75), overexpression of HER-2 (Score 2+) was observed ([Fig 5](#pone.0233232.g005){ref-type="fig"}, [Table 2](#pone.0233232.t002){ref-type="table"}). Labeling index (LI) measured based on Ki-67 positive tumor cells was 3.4--68.1% ([Fig 5](#pone.0233232.g005){ref-type="fig"}, [Table 2](#pone.0233232.t002){ref-type="table"}).

![**Immunohistochemistry staining of tree shrew mammary gland tumors with anti ER (tree shrew No. 48, 2 years 5 months old) and anti-PR (tree shrew No. 131, 3 years 7 months old) antibodies (bar = 100μm) (lower left and middle), and tree shrew tubulopapillary carcinomas with anti-HER-2 (tree shrew No.75: 6 years and 1 month old) (bar = 50μm lower; ×400) (upper right).** More than 10% of the tumor cell membrane was stained partially or weakly but entirely (upper right). In normal tissues of the tree shrew mammary gland, the expression of ER and PR was observed in the nucleus of ductal epithelial cells (upper left and middle). Ki-67+ mammary tumor cells (tree shrew No.75, 6 years and 1 month old) are also shown (lower right; ×400).](pone.0233232.g005){#pone.0233232.g005}

Mutations in PTEN and PIK3CA genes \[[@pone.0233232.ref012]\] were not observed in mammary tumors from tupaias No.75, 97, 185, and 211, after sequencing.

In addition to these markers, Nectin-4 has been also reported to be expressed in breast cancer cells \[[@pone.0233232.ref021]\] and Nectin-4 targeted oncolytic measles virus (MV) vector has been constructed \[[@pone.0233232.ref022]\]. To clarify the possibility that MV vector targeting Nectin-4 is applicable for the tree shrew mammary tumor model, we stained mammary tumor cells with anti-Nectin-4 antibody ([Fig 6](#pone.0233232.g006){ref-type="fig"}). Thus, 27.4% of cells could be stained with anti-Nectin-4 antibody using FACS.

![Nectin-4 staining of breast cancer cells (tree shrew No.155, 3 years 1 month old).\
Live single cells were calculated as 91.5 and 94.5% by size using the FACS verse. Nectin-4 positive cells were calculated to be 27.4% in living cells (lower right column).](pone.0233232.g006){#pone.0233232.g006}

X-ray CT analysis {#sec013}
-----------------

X-ray CT analysis was also performed on tree shrews with mammary tumor (No.26, [Fig 7](#pone.0233232.g007){ref-type="fig"}) using LCT-200 (Hitachi, Ltd., Tokyo, Japan) ([S1A Fig](#pone.0233232.s003){ref-type="supplementary-material"}). The entire bone and skull structures were also observed ([S1B Fig](#pone.0233232.s003){ref-type="supplementary-material"}, [S1C Fig](#pone.0233232.s003){ref-type="supplementary-material"}) and they did not show significant abnormality. Numerous sarcomas were observed in the outer layer of the skin (red arrows, [Fig 7A](#pone.0233232.g007){ref-type="fig"}). Intraperitoneally, there were endocrine tumors close to the liver and kidney ([Fig 7B and 7C](#pone.0233232.g007){ref-type="fig"}). Based on the position and pathologic features of the tumor in the intraperitoneal cavity, it was deduced as adrenocortical adenoma ([S2 Fig](#pone.0233232.s004){ref-type="supplementary-material"}).

![X-ray CT (LCT-200) analysis of a tumor-bearing tree shrew (No.26, 4 years 11 months old).\
(**A**) Three-dimensional (3D) analysis of whole tree shrew body. Position of sarcoma was indicated by red arrows. (**B**) 3D tomogram of tree shrew. Arrows indicating tumor tissues. (**C**) 3D analysis of tree shrew belly. Yellow arrows indicate the large intraperitoneal tumors.](pone.0233232.g007){#pone.0233232.g007}

Discussion {#sec014}
==========

The results in this study showed that tree shrews can develop spontaneous mammary tumors. The incidence rate of mammary tumors in female tree shrews was 24.6% (15/61). Findings based on the tree shrew lineage study suggest that inheritance should be a major determinant of the occurrence of spontaneous mammary tumors in tree shrews and the occurrence of juvenile breast carcinoma was also noted. The earliest onset of breast cancer in tree shrews was 10 months. A tree shrew of less than 4 years can be considered a juvenile, as tree shrews typically have a lifespan of about 7--8 years \[[@pone.0233232.ref004]\]. The factors responsible for the incidence of breast cancer in the juvenile are unclear at present, but inheritance might be a predisposing factor. Juvenile papillomatosis has been reported to be linked to strong family history, which may lead to the onset of proliferative diseases in women less than 30 years of age \[[@pone.0233232.ref023]\]. As malignant cases were only observed in older tree shrews (No. 131: 5 years and 6 months and No. 75: 6 years and 1 month), malignancy could be influenced by age dependent factor(s). A previous study reported the incidence rate of spontaneous mammary carcinoma in tree shrew as 0.44% in 4--6-year-olds \[[@pone.0233232.ref014]\]. Intraductal mammary carcinomas in tree shrews have also been reported \[[@pone.0233232.ref012], [@pone.0233232.ref024]\]. Therefore, the results in this study highlight the possibility that mammary gland tumors appearing in young tree shrews may turn malignant with age.

The positive ratio of ER was 63% and 100% tumor cases were PR positive, which was consistent with a previous report \[[@pone.0233232.ref012]\]. The variation in the ER and PR expression in the mammary gland tumors might be influenced by the periodical blood estrogen level that affects the expression of PR \[[@pone.0233232.ref025]\]. Also, a malignant case (No.75: 6 years and 1 month) showed HER-2 positive (Score 2+), clear invasion, atypical morphology of nucleus, and high growth activity (LI:68.1) indicating highly malignant mammary gland carcinoma. It has been reported that HER-2 overexpression is linked with malignancy \[[@pone.0233232.ref026]\]. In case No. 75, the expression of ER was negative and that of PR was low, showing that HER-2 expression might contribute to malignancy. However, further study is required to clarify HER-2 amplification using in situ hybridization. We also performed sequencing of PTEN and PIK3CA genes in tupaias No.75, 97, 185, and 211. However, we did not detect any mutations in these genes, as previously reported \[[@pone.0233232.ref012]\]. Further study is required for clarification of the gene mutations in spontaneous tupaia mammary tumors, which could shed light on the genetical aspects for familial inheritance of mammary tumors.

In this study, simultaneous or metachronous multiplex tumors were frequently observed (9/15; 60%). Incidence of tumor was frequently observed in multiple mammary glands. Except one malignant case (No. 75), all tumors were noninvasive. Moreover, level of ER expression showed variations in multiple tumors in one individual (No. 97) ([Table 2](#pone.0233232.t002){ref-type="table"}), suggesting that they did not share the site of origin and were not recurrent cases. Therefore, most of the simultaneous or metachronous multiplex tumors possibly originated from multiple sites.

Oncolytic virotherapy is one of the promising approaches for analyzing the therapeutic strategies of breast cancers \[[@pone.0233232.ref022], [@pone.0233232.ref027]\]. Tumor-expressing molecules like the epidermal growth factor receptor (EGFR) can be a suitable target for cancer therapy \[[@pone.0233232.ref028]--[@pone.0233232.ref030]\]. Nectin-4 is a diagnostic and therapeutic target for lung cancer \[[@pone.0233232.ref031]\] and breast carcinoma \[[@pone.0233232.ref032]\], and the epithelial cell receptor of measles virus \[[@pone.0233232.ref033]\]. Based on these observations, the measles virus vector has been developed for various cancers \[[@pone.0233232.ref022], [@pone.0233232.ref027], [@pone.0233232.ref033]\]. We observed the expression of nectin-4 on the surface of tree shrew mammary tumor cells. Also, X-ray CT analysis has made possible the observation of tumor tissues in the body of tree shrews. Therefore, the tree shrew model should contribute towards the development of therapeutic strategy for mammary tumors in future studies.

Supporting information {#sec015}
======================

###### Raw data of [Fig 1](#pone.0233232.g001){ref-type="fig"} (onset of mammary tumors in female tree shrews) was indicated.

(XLSX)

###### 

Click here for additional data file.

###### Analysis on liver (2--1) and brain (2--2) of tree shrew \#26 (4 years 11 months) by LCT-200.

(PDF)

###### 

Click here for additional data file.

###### 

(**A**) Outlook of CT LCT-200 (Hitachi Ltd., Tokyo Japan). (**B**) Whole body structure (upper) and bone structure (lower). (**C**) The skull structure of tree shrew (\#26, 4 years 11 months).

(PDF)

###### 

Click here for additional data file.

###### H&E staining of intraperitoneal tumor of tree shrew \#26.

(**A**) Tumor (upper, blue arrow) and liver (lower). (**B**) Tumor (blue arrow) and kidney (left). (**C**) Tumor (x40) (**D**) Tumor (x200), Bar-100μm.

(PDF)

###### 

Click here for additional data file.

###### J-score.

(DOCX)

###### 

Click here for additional data file.

###### HER-2 score.

(DOCX)

###### 

Click here for additional data file.

###### 

(DOCX)

###### 

Click here for additional data file.
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We would appreciate receiving your revised manuscript by Apr 24 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Yi Li, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note that the tree shrews were not euthanised at the end of the study. In the Methods, please report the outcome of the animals; for example, if they were used in other studies, or were returned to the Laboratory Animal Centre.

3\. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study\'s minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see <http://journals.plos.org/plosone/s/data-availability>.

Upon re-submitting your revised manuscript, please upload your study's minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

5\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: Yes

Reviewer \#3: N/A

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Authors bred and characterized 61 female tree shrews and identified 15 spontaneous mammary tumors. The incidence rate of mammary tumors was 24.6 % (15/61) and the average age of tumor incidence was 2 years 3 months. Unknown inherited factor(s) may paly a role in familial BC. Most cases were simple adenomas and two cases were tubulopapillary carcinomas. Over 90% cases were positive for both ERa and PR. These findings are quite interesting.

Major concerns:

1\. Whether pTEN and PI3KCA genes are mutated in these spontaneous mammary tumors should be validated.

2\. Ref 25 was incorrectly cited. Additionally, the following ref should be cited: characterization of spontaneous breast tumor in tree shrews (Tupaia belangeri chinenesis), Zoological Research, 2012，Feb. 33(1): 55−59.

3\. The pathological differences between this study and Ref 12 should be discussed. Simple adenomas may not be accurate. Please consult pathologist for the classification.

Reviewer \#2: Due to their structural differences between mouse and human mammary glands, commonly used mouse models of breast cancer have some limitations. Authors of this manuscript entitled "Pathological and genetic aspects of spontaneous mammary gland tumor in Tupaia belangeri (Tree shrew)" characterized the pathological and genetic aspects of spontaneous mammary tumors in Tupaia belangeri (tree shrew), which shows relatively high genetic homology and structural similarity to human mammary glands. Authors found that the tree shrews in their laboratory have high mammary tumor incidence rate (24.6%) and high rate of simultaneous or metachronous multiplex mammary tumors (60%). Some cases seemed to be of familial mammary gland tumors. Most tumors are benign adenoma and ER+. Two malignant mammary tumors (tubulopapillary carcinoma) were also observed. This work may provide a new animal model for breast cancer research. Future investigation on the genetic basis of familial cases may provide new insight into the mechanism of mammary tumorigenesis. The expression of Nectin-4, the receptor of measles virus, in some mammary tumor cells may provide a model to study the oncolytic virotherapy of breast cancer. The manuscript is overall well written. Following a few correction/modification may improve the manuscript.

1\. Typo: "Nectin-4 has been also been reported" (page 11) should be corrected.

2\. Figures 5 and 6 can be combined to save space.

3\. Please provide a little bit more information in the Figure legend of Figure 1.

Reviewer \#3: This interesting paper highlights pathological characteristics of another animal model of breast cancer, the tree shrew. While the pathological descriptions are evident, the manuscript does focus quite a bit on the familial inheritance of mammary tumors seen in their model. However the data supporting these observations is quite minimal aside from pedigree charting. Are these familial patterns driven by germline mutations that can be identified,particularly those associated with inherited forms of breast cancer. I think the genetic aspects should be explored more here for discussion, including sequencing of at least the major inherited drivers in breast cancer.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1: Authors bred and characterized 61 female tree shrews and identified 15 spontaneous mammary tumors. The incidence rate of mammary tumors was 24.6 % (15/61) and the average age of tumor incidence was 2 years 3 months. Unknown inherited factor(s) may paly a role in familial BC. Most cases were simple adenomas and two cases were tubulopapillary carcinomas. Over 90% cases were positive for both ERa and PR. These findings are quite interesting.

Major concerns:

1\. Whether pTEN and PI3KCA genes are mutated in these spontaneous mammary tumors should be validated.

In line with the reviewer's suggestions, we performed sequencing of PTEN and PIK3CA genes in the mammary tumors of tupaia No.75 (malignant, 6Y1M), No.97 (3Y11M), No.185 (2Y8M), and No.211 (10M), as reported previously (Xia et al., Eur. J. Cancer, 2014, reference \#12). However, we did not observe any mutations in these genes, as reported in reference \#12.

2\. Ref 25 was incorrectly cited. Additionally, the following ref should be cited: characterization of spontaneous breast tumor in tree shrews (Tupaia belangeri chinenesis), Zoological Research, 2012，Feb. 33(1): 55−59.

In line with the reviewer's comments, we have corrected reference 25 by replacing it with reference 12, and included the reference suggested by the reviewer \[Characterization of spontaneous breast tumor in tree shrews (Tupaia belangeri chinenesis), Zoological Research, 2012，Feb. 33(1): 55−59\].

3\. The pathological differences between this study and Ref 12 should be discussed. Simple adenomas may not be accurate. Please consult pathologist for the classification.

From the results of this study, mutations in PTEN and PIK3CA genes may not always be induced in spontaneous mammary tumors in tupaia (p11, lines 12-13). However, further study is required in this field. We have discussed these points on p14, lines 7-10.

We have discussed the pathological differences with a veterinary pathologist and changed "simple adenomas" to "intraductal papillary adenoma (duct papilloma)(IPA)", and included reference 15. We have also explained these findings in greater detail (p10, lines 11--15).

Reviewer \#2: Due to their structural differences between mouse and human mammary glands, commonly used mouse models of breast cancer have some limitations. Authors of this manuscript entitled "Pathological and genetic aspects of spontaneous mammary gland tumor in Tupaia belangeri (Tree shrew)" characterized the pathological and genetic aspects of spontaneous mammary tumors in Tupaia belangeri (tree shrew), which shows relatively high genetic homology and structural similarity to human mammary glands. Authors found that the tree shrews in their laboratory have high mammary tumor incidence rate (24.6%) and high rate of simultaneous or metachronous multiplex mammary tumors (60%). Some cases seemed to be of familial mammary gland tumors. Most tumors are benign adenoma and ER+. Two malignant mammary tumors (tubulopapillary carcinoma) were also observed. This work may provide a new animal model for breast cancer research. Future investigation on the genetic basis of familial cases may provide new insight into the mechanism of mammary tumorigenesis. The expression of Nectin-4, the receptor of measles virus, in some mammary tumor cells may provide a model to study the oncolytic virotherapy of breast cancer. The manuscript is overall well written. Following a few correction/modification may improve the manuscript.

1\. Typo: "Nectin-4 has been also been reported" (page 11) should be corrected.

We have corrected this sentence (p11, line 5 from the bottom).

2\. Figures 5 and 6 can be combined to save space.

We have combined Figures 5 and 6.

3\. Please provide a little bit more information in the Figure legend of Figure 1.

In line with the reviewer's comments, we have updated the figure legend with more information.

Reviewer \#3: This interesting paper highlights pathological characteristics of another animal model of breast cancer, the tree shrew. While the pathological descriptions are evident, the manuscript does focus quite a bit on the familial inheritance of mammary tumors seen in their model. However the data supporting these observations is quite minimal aside from pedigree charting. Are these familial patterns driven by germline mutations that can be identified,particularly those associated with inherited forms of breast cancer. I think the genetic aspects should be explored more here for discussion, including sequencing of at least the major inherited drivers in breast cancer.

We thank the reviewer for their helpful comments. In line with these comments, we sequenced the PTEN and PIK3CA genes in different tupaia tumors \[tupaia No.75 (malignant, 6Y1M), No.97 (3Y11M), No.185 (2Y8M), and No.211 (10M)\]. However, we did not detect any mutations in these genes, which was reported previously (reference 12). We have discussed these findings in the discussion (p14, lines 7--11).
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Dear Dr. Tsukiyama-Kohara,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Yi Li, Ph.D.

Academic Editor

PLOS ONE
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Pathological and genetic aspects of spontaneous mammary gland tumor in Tupaia belangeri (Tree shrew)

Dear Dr. Tsukiyama-Kohara:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Yi Li

Academic Editor

PLOS ONE
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